{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T13:09:14Z","timestamp":1774789754623,"version":"3.50.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Crohn\u2019s disease [CD] and ulcerative colitis [UC], the main inflammatory bowel diseases [IBD] in humans, are chronic, immune-inflammatory diseases, the pathogenesis of which suggests a complex interaction between environmental factors and genetic susceptibility. These disabling conditions affect millions of individuals and, together with the drugs used to treat them, can put patients at risk of developing complications and other conditions. This is particularly relevant today, as coronavirus disease [Covid-19] has rapidly spread from China to countries where IBD are more prevalent, and there is convincing evidence that Covid-19-mediated morbidity and mortality are higher in subjects with comorbidities. The primary objectives of this Viewpoint are to provide a focused overview of the factors and mechanisms by which the novel severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] infects cells and to illustrate the link between such determinants and intestinal inflammation. We also provide clues about the reasons why the overall IBD population might have no increased risk of developing SARS-CoV-2 infection and highlight the potential of cytokine blockers, used to treat IBD patients, to prevent Covid-driven pneumonia.<\/jats:p>","DOI":"10.1093\/ecco-jcc\/jjaa061","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T12:08:07Z","timestamp":1584965287000},"page":"1334-1336","source":"Crossref","is-referenced-by-count":150,"title":["Are Patients with Inflammatory Bowel Disease at Increased Risk for Covid-19 Infection?"],"prefix":"10.1093","volume":"14","author":[{"given":"Giovanni","family":"Monteleone","sequence":"first","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u2018TOR VERGATA\u2019, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Ardizzone","sequence":"additional","affiliation":[{"name":"Gastrointestinal Unit, ASST-Fatebenefratelli Sacco \u2013 Department of Biochemical and Clinical Sciences \u2018L. Sacco\u2019, University of Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,3,26]]},"reference":[{"key":"2020091607142657100_CIT0001","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1126\/science.1106442","article-title":"Immunity, inflammation, and allergy in the gut","volume":"307","author":"Macdonald","year":"2005","journal-title":"Science"},{"key":"2020091607142657100_CIT0002","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.cgh.2014.01.021","article-title":"Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review","volume":"12","author":"Dulai","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020091607142657100_CIT0003","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"2020091607142657100_CIT0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"2020091607142657100_CIT0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-5793(02)03640-2","article-title":"Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme","volume":"532","author":"Harmer","year":"2002","journal-title":"FEBS Lett"},{"key":"2020091607142657100_CIT0006","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.3786","article-title":"Detection of SARS-CoV-2 in different types of clinical specimens","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"2020091607142657100_CIT0007","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.02.055","article-title":"Evidence for gastrointestinal infection of SARS-CoV-2","author":"Xiao","year":"2020","journal-title":"Gastroenterology"},{"key":"2020091607142657100_CIT0008","article-title":"Imbalance of the renin\u2013angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?","author":"Garg","year":"2019","journal-title":"Gut"},{"key":"2020091607142657100_CIT0009","doi-asserted-by":"crossref","first-page":"3950628","DOI":"10.1155\/2019\/3950628","article-title":"Quantitative proteomic analysis reveals the deregulation of nicotinamide adenine dinucleotide metabolism and CD38 in inflammatory bowel disease","volume":"2019","author":"Ning","year":"2019","journal-title":"Biomed Res Int"},{"key":"2020091607142657100_CIT0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.02.026","article-title":"COVID-19 Spike-host cell receptor GRP78 binding site prediction","author":"Ibrahim","year":"2020","journal-title":"J Infect"},{"key":"2020091607142657100_CIT0011","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fcimb.2020.00021","article-title":"Fecal serine protease profiling in inflammatory bowel diseases","volume":"10","author":"Jablaoui","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"2020091607142657100_CIT0012","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV\u2013a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"2020091607142657100_CIT0013","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/HYPERTENSIONAHA.109.138420","article-title":"Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension","volume":"55","author":"Wysocki","year":"2010","journal-title":"Hypertension"},{"key":"2020091607142657100_CIT0014","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1042\/CS20200163","article-title":"Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?","volume":"134","author":"Wysocki","year":"2020","journal-title":"Clin Sci"},{"key":"2020091607142657100_CIT0015","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1177\/1470320314521086","article-title":"Upregulation of circulating components of the alternative renin\u2013angiotensin system in inflammatory bowel disease: a pilot study","volume":"16","author":"Garg","year":"2015","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2020091607142657100_CIT0016","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J Pathol"},{"key":"2020091607142657100_CIT0017","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.crohns.2010.02.009","article-title":"Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD","volume":"4","author":"Govani","year":"2010","journal-title":"J Crohns Colitis"},{"key":"2020091607142657100_CIT0018","first-page":"E005","article-title":"Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies","volume":"36","author":"Chen","year":"2020","journal-title":"Zhonghua Shao Shang Za Zhi"},{"key":"2020091607142657100_CIT0019","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"key":"2020091607142657100_CIT0020","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.coph.2011.09.013","article-title":"Emerging immunological targets in inflammatory bowel disease","volume":"11","author":"Monteleone","year":"2011","journal-title":"Curr Opin Pharmacol"},{"key":"2020091607142657100_CIT0021","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2217\/imt-2016-0020","article-title":"Immunotherapeutic implications of IL-6 blockade for cytokine storm","volume":"8","author":"Tanaka","year":"2016","journal-title":"Immunotherapy"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaa061\/32978985\/jjaa061.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/9\/1334\/33751690\/jjaa061.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/9\/1334\/33751690\/jjaa061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T12:00:28Z","timestamp":1600257628000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/14\/9\/1334\/5811674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,26]]},"references-count":21,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,3,26]]},"published-print":{"date-parts":[[2020,9,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa061","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9,1]]},"published":{"date-parts":[[2020,3,26]]}}}